Physician-induced torsade de pointes - Therapeutic implications

Cardiovascular Drugs and Therapy

Volumn 16, Issue 2, 2002, Pages 101-109

  Haverkamp, Wilhelm ^a   Mönnig, Gerold ^a   Schulze Bahr, Eric ^a   Haverkamp, Franziska ^a   Breithardt, Günter ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Drug metabolism; Drug related adverse effect; Iatrogenic effect; Long QT syndrome; Proarrhythmia; QT interval; Sudden cardiac death; Torsade de pointes; Ventricular tachycardia

Indexed keywords

CARDIOVASCULAR AGENT; ALMOKALANT; AMANTADINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; DOFETILIDE; ELECTROLYTE; IBUTILIDE; IONIC CONTRAST MEDIUM; ISOPRENALINE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; SEMATILIDE; SOTALOL;

CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; ELECTROCARDIOGRAPHY; GENETICS; HUMAN; IATROGENIC DISEASE; LONG QT SYNDROME; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; TORSADE DES POINTES; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE PREDISPOSITION; DRUG METABOLISM; GENE MUTATION; HEART REPOLARIZATION; PRIORITY JOURNAL; QT INTERVAL; SUDDEN DEATH;

CARDIOVASCULAR AGENTS; DRUG TOXICITY; ELECTROCARDIOGRAPHY; HUMANS; IATROGENIC DISEASE; LONG QT SYNDROME; RISK FACTORS; TORSADES DE POINTES; HUMAN;

EID: 0035997521     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015797214679     Document Type: Article

References (42)

1. Un chapitre nouveau d'electrocardiographie: Les variations progressive de l'amplitude de l'electrocardiogramme
2. Torsade de pointes
3. Torsade de pointes
4. Taking the "idio" out of "idiosyncratic": Predicting torsades de pointes
5. Congenital and acquired long QT syndrome
6. The long QT syndromes: Genetic basis and clinical implications
7. Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients
8. Congenital deaf-tourism, functional heart disease with prolongation of the QT interval, and sudden death
9. Aritmie cardiache rare delleta pedriatrica: Accessi per fibrillazione ventricalare parossistica
10. A new familial cardiac syndrome in children
11. Inherited long QT syndromes - A paradigm for understanding arrhythmogenesis
12. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management
13. The potential for QT prolongation by non-antiarrhythmic drugs. Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology
14. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias
15. Torsades de pointes due to quinidine: Observations in 31 patients
16. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care
17. Proarrhythmia with class III antiarrhythmic drugs: Types, risks, and management
18. Efficacy and safety of d, l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest
19. Sex difference in risk of torsade de pointes with d, l-sotalol
20. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: A placebo-controlled, implantable cardioverter-defibrillator-based evaluation
21. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the Generation of U waves, triggered activity and torsade de pointes
22. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
23. A common polymorphism associated with antibiotic-induced cardiac arrhythmia
24. Clinical aspects of ventricular arrhythmias associated with QT prolongation
25. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: A prospective study
26. Torsade de pointes secondary to d, l-sotalol after catheter ablation of incessant atrioventricular reentrant tachycardia - Evidence for a significant contribution of the "cardiac memory"
27. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence
28. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
29. Antiarrhythmic agents: Drug interactions of clinical significance
30. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences
31. Pacing-induced heart failure causes a reduction of delayed rectifier potassium currents along with decreases in calcium and transient outward currents in rabbit ventricle
32. Drug therapy for torsade de pointes
33. Magnesium therapy for torsade de pointes
34. Treatment of torsade de pointes with magnesium sulfate
35. Electrophysiologic effects of potassium channel openers
36. Antiarrhythmic actions of the ATP regulated K+ current activated by pinacidil
37. Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators
38. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization
39. Nicorandil suppresses early afterdepolarizations and ventricular arrhythmias induced by cesium chloride in rabbits in vivo
40. Improvement of repolarization abnormalities by a K+ channel opener in the LQTI form of congenital long-QT syndrome
41. Isoproterenol antagonizes prolongation of refractory period by the class 111 antiarrhythmic agent E-4031 in guinea pig myocytes